Invention Grant
- Patent Title: URAT1 inhibitor for promoting uric acid excretion
-
Application No.: US16617426Application Date: 2018-05-25
-
Publication No.: US11597725B2Publication Date: 2023-03-07
- Inventor: Dongfang Shi , Jianghua Zhu , Jie Gu , Xi Cheng , Yan Yang , He Zhou , Pengfei Li , Fan Wu
- Applicant: JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD.
- Applicant Address: CN Zhenjiang
- Assignee: JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD.
- Current Assignee: JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD.
- Current Assignee Address: CN Zhenjiang
- Agency: CBM Patent Consulting, LLC
- Priority: CN201710386922.4 20170526
- International Application: PCT/CN2018/088400 WO 20180525
- International Announcement: WO2018/214961 WO 20181129
- Main IPC: C07D471/04
- IPC: C07D471/04 ; A61P19/06 ; C07D231/56 ; C07D487/04 ; C07D491/052

Abstract:
The present invention belongs to the field of medicinal chemistry. Specifically disclosed is a class of URAT1 inhibitors for promoting uric acid excretion, which are compounds as represented by the structure of formula (I) or pharmaceutically acceptable salts thereof. Experiments show that the compounds provided by the present invention have a very good inhibitory effect on the transport of uric acid by hURAT1 in HEK293 transfected cells, and that such compounds have a good application prospect in the treatment of hyperuricemia or gout.
Public/Granted literature
- US20200262832A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION Public/Granted day:2020-08-20
Information query